Zweig-DiMenna Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Zweig-DiMenna Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-110,260	Closed	-$21M	–	291
2015 Q4	$21M	Sell	110,260 -104,686	-49%	-$18.3M	1.05%	31
2015 Q3	$33.6M	Buy	+214,946	New	+$39.2M	1.46%	14
2015 Q2	–	Sell	-106,823	Closed	-$18.5M	–	329
2015 Q1	$18.5M	Sell	106,823 -11,864	-10%	-$2.15M	0.78%	44
2014 Q4	$22M	Sell	118,687 -57,504	-33%	-$10.7M	0.94%	35
2014 Q3	$29.2M	Buy	176,191 +46,091	+35%	+$7.57M	1.28%	19
2014 Q2	$20.3M	Buy	+130,100	New	+$20.5M	0.93%	38
2013 Q3	–	Sell	-38,750	Closed	-$3.57M	–	275
2013 Q2	$3.57M	Buy	+38,750	New	+$3.73M	0.14%	134

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Zweig-DiMenna Associates's ALXN Position: Q1 2016 in Review

Zweig-DiMenna Associates sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 110,260 shares — an estimated $21M sold.

Zweig-DiMenna Associates first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $33.6M in Q3 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Zweig-DiMenna Associates reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Zweig-DiMenna Associates sold 110,260 Alexion Pharmaceuticals shares in Q1 2016, an estimated $21M.
Zweig-DiMenna Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Zweig-DiMenna Associates's Alexion Pharmaceuticals position peaked at $33.6M in Q3 2015.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2016, filed 10 May 2016.